Hepatitis Drug Development Pipeline Review, 2018 – ResearchByMarkets.com

PUNE, India, September 05, 2018 /ResearchByMarkets/— Hepatitis Drug Development Pipeline Review, 2018

This report provides an overview of the pipeline landscape for hepatitis infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hepatitis A, hepatitis B, hepatitis D and hepatitis E, and features dormant and discontinued products.

Hepatitis refers to inflammation of the liver and is most commonly caused by viral infections. Hepatitis A and E are typically caused by ingestion of contaminated food or water. Symptoms of hepatitis A infection include fatigue, nausea and vomiting, loss of appetite, dark urine, muscle pain and yellowing of the skin and eyes.

Risk factors include a weakened immune system and use of injected or non-injected illicit drugs. Symptoms of hepatitis E include yellowing of the skin, dark urine, fever, fatigue, joint pain, nausea, a loss of appetite and pain in the abdomen.

Hepatitis B and hepatitis D infection typically occur as a result of contact with infected body fluids. Transmission of hepatitis B can occur via sexual contact, injection drug use or transfusions of contaminated blood and blood products. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes, dark urine, extreme fatigue, nausea, vomiting and abdominal pain.

Hepatitis D infection only occurs in persons previously infected with hepatitis B, as the hepatitis D virus can only replicate in the presence of hepatitis B. The co-infection of hepatitis B and hepatitis D is associated with greater disease severity than hepatitis B infection alone.

Companies operating in this pipeline space include Cadila Healthcare and Chongqing Zhifei Biological Products.



– Which companies are the most active within each pipeline?
– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
– What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

– Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
– Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
– Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
– Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


Companies Mentioned:

Abivax SA
AiCuris GmbH & Co KG
AIMM Therapeutics BV
Akshaya Bio Inc
Alnylam Pharmaceuticals Inc
Altimmune Inc
Altravax Inc
Amarna Therapeutics BV
Arbutus Biopharma Corp
Arcturus Therapeutics Ltd
Arrowhead Pharmaceuticals Inc
Ascentage Pharma Group Corp Ltd
Assembly Biosciences Inc
Aucta Pharmaceuticals LLC
Beijing Kawin Technology Share-Holding Co Ltd
Beijing Minhai Biotechnology Co Ltd
Benitec Biopharma Ltd
Biological E Ltd
BioStar Pharmaceuticals Inc
Biotron Ltd
Bolder Biotechnology Inc
BrightGene Bio-Medical Technology Co Ltd
Bukwang Pharm Co Ltd
Cadila Healthcare Ltd
CaroGen Corp
Celltrion Inc
China National Pharmaceutical Group Corp
Chong Kun Dang Pharmaceutical Corp
Chongqing Zhifei Biological Products Co Ltd
Chromis Therapeutics Inc
Cocrystal Pharma Inc
ContraVir Pharmaceuticals Inc
CyTuVax BV
DelSiTech Ltd
Dicerna Pharmaceuticals Inc
Dong-A Socio Holdings Co Ltd
Ensemble Therapeutics Corp
Enyo Pharma SA
Excision BioTherapeutics Inc
F. Hoffmann-La Roche Ltd
GC Pharma
GeneCure LLC
GeoVax Labs Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
Huons Global Co Ltd
Immunotope Inc
Indian Immunologicals Ltd
Inovio Pharmaceuticals Inc
Intellia Therapeutics Inc
Ionis Pharmaceuticals Inc
ISA Pharmaceuticals BV
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Johnson & Johnson
Kainos Medicine Inc
Kineta Inc
LG Chem Ltd
Microbiotix Inc
MultiCell Technologies Inc
Oncolys BioPharma Inc
Pfenex Inc
PharmaEssentia Corp
Profectus BioSciences Inc
Qilu Pharmaceutical Co Ltd
Replicor Inc
Rodos BioTarget GmbH
Samjin Pharm Co Ltd
Sanofi Pasteur SA
Scynexis Inc
Shantha Biotechnics Pvt Ltd
Sino Biopharmaceutical Ltd
Sinovac Biotech Ltd
Spring Bank Pharmaceuticals Inc
TCM Biotech International Corp
Theravectys SA
THEVAX Genetics Vaccine USA Inc
Transgene SA
Vaccitech Ltd
Vaxine Pty Ltd
VBI Vaccines Inc
Vical Inc
ViroStatics srl
VLP Biotech Inc

Get in touch with us:
Ritesh Tiwari, Director
USA: +1-800-416-3124

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: enquiry@researchbymarkets.com *Industry Press Release is a part of Research By Markets.